SG Americas Securities LLC Buys New Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

SG Americas Securities LLC purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,710 shares of the company’s stock, valued at approximately $321,000. SG Americas Securities LLC owned 0.06% of 4D Molecular Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in FDMT. Goldman Sachs Group Inc. lifted its holdings in 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock valued at $16,539,000 after acquiring an additional 658,069 shares during the period. Wellington Management Group LLP boosted its holdings in shares of 4D Molecular Therapeutics by 4.5% in the 4th quarter. Wellington Management Group LLP now owns 180,475 shares of the company’s stock worth $3,656,000 after purchasing an additional 7,753 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after purchasing an additional 3,026 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of 4D Molecular Therapeutics by 92.2% in the 1st quarter. Principal Financial Group Inc. now owns 19,185 shares of the company’s stock worth $611,000 after purchasing an additional 9,204 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of 4D Molecular Therapeutics by 29.9% in the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock worth $1,717,000 after purchasing an additional 12,400 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FDMT. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Royal Bank of Canada restated an “outperform” rating and set a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Chardan Capital boosted their price objective on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Finally, Leerink Partners reissued an “outperform” rating and issued a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

4D Molecular Therapeutics Stock Up 0.9 %

NASDAQ FDMT opened at $8.53 on Friday. 4D Molecular Therapeutics, Inc. has a 52-week low of $8.37 and a 52-week high of $36.25. The business’s 50-day moving average price is $13.03 and its 200 day moving average price is $19.57. The firm has a market cap of $441.03 million, a P/E ratio of -3.50 and a beta of 2.77.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.09. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $1.90 million. As a group, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.74 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.